

Product Type	Product Profile	Product Presentation	Indication	Status Reason	Approved Date
Medicine	Psilocybin	Tablet	Treatment resistant depression	Approved	25/07/2023
Medicine	Psilocybin	Capsule	Treatment resistant depression	Approved	2/11/2023
Medicine	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved	2/11/2023
Medicine	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved	7/12/2023
Medicine	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved	9/01/2024
Medicine	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved	7/12/2023
Medicine	Psilocybin	Capsule	Treatment resistant depression	Approved	7/12/2023
Medicine	Psilocybin	Capsule	Treatment resistant depression	Approved	9/02/2024
Medicine	Psilocybin	Capsule	Treatment resistant depression	Approved	23/01/2024
Medicine	Psilocybin	Capsule	Treatment resistant depression	Approved	30/01/2024
Medicine	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved	30/01/2024
Medicine	3,4-Methylenedioxymethamphetamine (MDMA)	Capsule	Post Traumatic Stress Disorder	Approved	4/04/2024